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Background: Nonadherence to prescribed medications is a
common problem in dermatology, and assessing adherence
can be difficult. Electronic monitors are not always practical,
but self-report measures may be less reliable.
Purpose: To review the literature for self-report instruments
and electronic monitors used to measure medication adher-
ence in patients with chronic disease.
Methods: A PubMed literature search was conducted using
the terms ‘scale,’ ‘measure,’ ‘self-report,’ ‘electronic,’ and
‘medication adherence.’ Relevant articles were reviewed
and selected if they addressed self-report or electronic
measures of adherence in chronic disease.
Results: Eleven self-report instruments for the measure-
ment of adherence were identified. Four were validated
using electronic monitors. All produced an estimate of
adherence that correlated with actual behavior, although
this correlation was not strong for any of the measures.
None of the scales was tested in patients who had derma-
tologic disease and/or used topical medications. Several
electronic monitoring systems were identified, including pill
counts, pharmacy refill logs, and the Medication Event
Monitoring System (MEMS
s
). Validity was higher among
electronic monitoring systems compared with self-report
measures.
Conclusion: While several self-report measures of adher-
ence have been validated in chronic disease populations,
their relevance in dermatology patients has not been stu-
died. A dermatology-specific instrument for the measure-
ment of adherence would contribute to improved outcomes;
until such a tool exists, researchers and clinicians should
consider nonadherence as a possible factor in skin disease
that is not responsive to treatment. Electronic monitoring
provides the most reliable means of measuring adherence,
and may provide additional clues to identify barriers to
adherence.
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ADHERENCE TO prescribed medication regi-mens is a major contributor to the success-
ful treatment of dermatologic problems. Higher
levels of adherence have been linked to better
outcomes in both atopic dermatitis and psoriasis,
and this relationship likely pertains with many
other types of skin disease (1, 2). Unfortunately,
roughly one-third to one-half of the patients
prescribed medications for a dermatologic com-
plaint are nonadherent (3). Identifying indivi-
duals who do not adhere to treatment
recommendations is an important way to im-
prove patient outcomes.
Accurate and reliable measurement of adher-
ence behavior is difficult. Many approaches to
measuring adherence have been described, in-
cluding patient self-report, physician estimates,
pharmacy refill information, pill counts, serologic
drug concentrations, physiologic outcomes, and
electronic monitoring (4). Of these methods, elec-
tronic monitoring may provide the best estimate
of patient adherence (5, 6). The medication elec-
tronic monitoring system (MEMS) is an example
of a device that can document actual use patterns
by recording the date and times at which medica-
tion bottles or tubes are opened (5). Although the
method has been used successfully, measuring
adherence using MEMS is expensive and not
always practical (4). Self-report measures have
the advantage of being relatively quick, inexpen-
sive, and easy to use (7). Furthermore, such
measures can have the added benefit of identify-
ing barriers to adherence that may be amenable
to intervention (8).
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This review summarizes existing self-report
and electronic measures to detect or predict
nonadherence and evaluates their utility in der-
matology.
Methods
A PubMed literature search was conducted to
identify relevant articles using the terms ‘scale,’
‘measure,’ ‘screening,’ ‘electronic,’ and ‘medica-
tion adherence.’ Over 500 articles were reviewed
and selected if they addressed self-report or
electronic measures of medication adherence in
chronic disease. These measures could be rele-
vant for chronic disease in general or specific
conditions. Articles were chosen that described
the scales currently used in clinical or research
practice or reported newly developed scales.
Bibliographies were cross-referenced when ap-
plicable. Only English-language articles were in-
cluded. Articles were excluded if (1) adherence
was measured using a method other than self-
report or electronic; (2) questions were so specific
to the disease for which the measure was devel-
oped that they could not be adapted for use in
other disciplines (e.g. measures developed for
patients with psychosis); (3) the measure in-
cluded only one item; or (4) the measure assessed




Eleven measures of self-reported adherence to
medication were selected for review. These mea-
sures were selected because they attempted to
assess adherence in patients with chronic disease
and also had data to demonstrate their ability to
predict adherence. Although they were all de-
signed for the same purpose, there was consider-
able variation between measures (Table 1). All
measures were designed to be completed by
patients, with the length of the questionnaires
ranging from 4 to 30 items. The format of the
measures varied. While most used dichotomous
yes/no answers or three to eight-point response
scales, the MASRI included a visual analog scale
and the Brief Medication Questionnaire required
patients to write the names and dosing schedules
for each of their medications. The ASRQ asked
patients to identify themselves with one of six
descriptions of patient adherence behavior.
With the exception of the Beliefs about Medi-
cines Questionnaire and the SOC, all of the
measures reported were tested initially in a
population of patients with a single, specific
chronic disease. None of the measures specifi-
cally addressed dermatologic conditions. Of the
measures reviewed, Morisky’s four-item scale,
first used in hypertensive patients, has been
used most extensively in other diseases; however,
no published validation of the measure in non-
hypertensive patients was found in the literature.
Part A of the MASRI was tested in a population
of 55 systemic lupus erythematous patients using
pharmacy refill information and was shown to
have a sensitivity of 61–67% and a specificity of
65–68% (17). The only measures for which gen-
eralizability without modification would be diffi-
cult are the Brief Medication Questionnaire and
ASRQ, in which questions refer specifically to the
pills taken and the bottles in which they were
dispensed, and the Admitted Nonadherence and
Risk for Nonadherence measures, in which some
questions are applicable only to asthma patients.
Electronic measures
The ability of self-report measures to capture
actual adherence behavior was evaluated using
a variety of methods. Four instruments – the
ASRQ, Brief Medication Questionnaire, MASRI,
and SOC – used MEMS data to show the correla-
tion between self-reported and actual adherence.
Morisky and his collaborators used physiologic
outcomes to assess actual adherence; in turn, the
SEAMS used Morisky’s four-item scale as its
criterion standard. Two measures, the BBQ and
the Beliefs about Medicines Questionnaire, used
nonvalidated self-report measures of adherence
as markers for actual adherence. Bauman and
colleagues used morbidity data to reflect actual
adherence in the evaluation of the Admitted
Nonadherence and Risk for Nonadherence
scales.
Electronic adherence monitoring systems may
provide a more reliable means of assessing ad-
herence to both oral and topical medications. The
Medication Event Monitoring System (MEMS
s
,
AARDEX Corp., Fremont, CA, USA) include
microprocessors in the bottle cap of a standard
medication bottle that record each time and date
the bottle is opened and the interval since the last
bottle opening (18). MEMS devices have been


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Assessing adherence to dermatology treatments
vascular medications and to highly active anti-
retroviral therapy for human immunodeficiency
virus (19, 20). Adherence to topical medications
can also be monitored using MEMS, which may
provide clinical utility in dermatologic conditions
such as atopic dermatitis and psoriasis. In one
study of 0.1% triamcinolone ointment use in 26
children with atopic dermatitis, the mean adher-
ence over the 8-week study was dismal at 32%
(21).
Comparison of data among different adherence
monitoring methods for topical medications has
revealed higher self-reported adherence rates
compared with electronic monitoring. Carroll
et al. (22) compared the medication logs, medica-
tion weights, and electronic adherence measures
in 30 patients with psoriasis. Adherence rates
measured by medication logs and weights were
consistently higher than those of the electronic
monitors. Another study comparing pill counts
and electronic monitoring in hypertensive pa-
tients showed that pill counts overestimate ad-
herence (23). MEMS also provides information on
the dynamic phases of adherence, including
quality of execution (when patients begin a new
medication regimen) and persistence (including
drug holidays and early discontinuation); this
information is not revealed by simply monitoring
the pill counts (24). MEMS devices may be used
to provide a more accurate assessment of patient
adherence, in addition to potentially revealing
barriers to adherence such as complex dosing
regimens.
Other ‘electronic’ methods have been used to
measure patient adherence, such as analyzing
serum drug levels at office visits. These spot
serum drug levels may not correlate with daily
steady-state concentrations, however, due to pos-
sible influences of other pharmacokinetic and
pharmacodynamic variables (25). This issue is
further compounded by so-called ‘white coat’
adherence, with patients being more likely to
take their medications around the time of office
visits (25). Pharmacy records of prescription re-
fills have also been used to measure adherence;
the problems with this method include patient
utilization of multiple pharmacies and the as-
sumption that ‘a prescription filled is a prescrip-
tion taken’ (26). The validity of self-report
measures was also questioned in a study of
college students with acne, with a sensitivity of
0.55 and a specificity of 0.72 compared with
concurrent observers’ examinations (27). Poor
adherence is a major contributor to treatment
failures, which in turn leads to increased health
care costs.
Discussion
Many self-report measures of adherence in
chronic disease have been developed, which
differ with regard to their format, their ability
to reflect actual adherence, and the patient popu-
lation in which they were studied. However, they
all share a relatively poor ability to predict
patient adherence. Furthermore, none has looked
specifically at the measurement of adherence in
patients with skin disease.
The limits of self-report measures of adherence
are well known. Patients do not always accu-
rately remember their own behavior and, even if
they do, may misrepresent their actual behavior
due to concern about how providers will view
them (4). Indeed, self-report measures often over-
estimate actual use (28). In one sample of psor-
iasis patients, patient logs reported 87%
adherence when electronic monitoring revealed
adherence rates of only 55% (22).
Many of the measures included in this review
use known risk factors for nonadherence to pre-
dict patients’ adherence behaviors. Among many
other variables, quality of life influences adher-
ence; in an Italian group of outpatient dermatol-
ogy patients, poor quality of life was associated
with lower satisfaction with care, and dissatisfac-
tion with care predicted poor treatment adher-
ence (29, 30). The relationship between poor
quality of life and nonadherence is counterintui-
tive, as one might expect those whose lives are
most affected by their skin disease to have the
greatest motivation for improvement. However,
poor quality of life has been repeatedly asso-
ciated with nonadherence.
The Skindex, a self-report quality of life mea-
sure, asks patients to indicate the frequency
with which their skin condition causes symp-
toms, emotional distress, or functional limitations
on a five-point scale; higher scores indicate
worse quality of life (31). Recent work by Jones-
Caballero suggests a relationship between Skin-
dex-29 and adherence to acne medications:
young females with high scores and males with
low scores on the Skindex-29 are more likely to be
nonadherent (32). Results from another self-
report measure of quality of life, the Dermatology
Life Quality Index (DLQI), have linked poor
256
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quality of life to nonadherence in both acne and
psoriasis patients (33, 34).
While the relationship between quality of life
and nonadherence is not strong enough to use
either the Skindex or the DLQI as measures of
adherence, the data from these studies make an
important point: patients do not always behave
in predictable ways. This unpredictability under-
scores the value of self-report and electronic tools
to measure adherence. Electronic monitoring
may provide the most reliable means of measur-
ing adherence, in addition to potentially provid-
ing an insight into why patients are nonadherent.
The MEMS system, although costly and not
practical for widespread clinical use, is consid-
ered the current gold standard for medication
adherence monitoring. Specific measures vali-
dated for use in dermatology are needed to
improve clinical outcomes and facilitate mean-
ingful research. Until such instruments are devel-
oped, clinicians and researchers should be
cognizant that nonadherence is common and
often a factor in skin disease resistant to treat-
ment.
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